Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Bromocriptine products were previously approved by the FDA for the treatment of pit...

Descripción completa

Detalles Bibliográficos
Autor principal: Keche, Yogendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications Pvt Ltd 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147101/
https://www.ncbi.nlm.nih.gov/pubmed/21814451
http://dx.doi.org/10.4103/0975-7406.67000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147101/
https://www.ncbi.nlm.nih.gov/pubmed/21814451
http://dx.doi.org/10.4103/0975-7406.67000

Ejemplares similares